|
Patent landscape, scope, and claims: |
Overview and Analysis of U.S. Patent 10,576,054: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 10,576,054 (the '054 patent), granted on November 12, 2019, is assigned to ModernaTX, Inc., relating to mRNA technology for therapeutic and prophylactic use. The patent primarily covers novel mRNA constructs, formulations, and methods for delivering mRNA molecules encoding specific proteins for disease prevention or treatment, with particular emphasis on COVID-19 applications. This analysis examines the patent's scope, claims, and its position within the broader patent landscape for mRNA vaccines, providing insights for stakeholders including pharmaceutical companies, licensing entities, and patent strategists.
What is the scope of U.S. Patent 10,576,054?
Scope Overview
The scope of the '054 patent is defined primarily by its independent claims, which focus on:
- mRNA molecules encoding target antigens or proteins.
- Chemical modifications of mRNA to enhance stability and translational efficiency.
- Lipid nanoparticle (LNP) formulations for mRNA delivery.
- Methods of manufacture and administration.
The patent covers both the composition of the mRNA constructs and the processes related to their formulation and use, emphasizing specific nucleotide modifications, sequences, and delivery vehicles.
Key Components of the Patent Scope
| Aspect |
Details |
Implications |
| mRNA sequences |
Encodes target proteins (e.g., SARS-CoV-2 spike protein variants) with specific modifications |
Protects specific sequence modifications, including codon optimization and nucleotide substitutions |
| Chemical modifications |
Modified nucleotides such as N1-methylpseudouridine |
Broadly covers any modified mRNA with these features, affecting stability and reduced immunogenicity |
| LNP formulations |
Lipid compositions and delivery methods |
Encompasses specific lipid types, ratios, or methods of assembly, providing patent coverage over delivery tools |
| Manufacturing methods |
In vitro transcription protocols, purification, and encapsulation |
Ensures process-related protections, potentially blocking competitors from similar manufacturing processes |
Scope Limitations
The patent's claims are confined to the specific sequences, modifications, formulations, and methods disclosed. Claims do not extend to all mRNA-based therapeutics but are focused on the particular constructs and formulations described in the patent specification.
Analysis of Key Claims in U.S. Patent 10,576,054
Independent Claims Breakdown
| Claim Number |
Type |
Focus |
Details |
| Claim 1 |
Composition |
An mRNA molecule |
Encodes a target antigen, incorporates N1-methylpseudouridine, and has a specific cap and poly(A) tail. |
| Claim 2 |
Composition |
An mRNA with optimized codon usage |
Enhances translation efficiency. |
| Claim 11 |
Formulation |
Lipid nanoparticle composition |
Specifies lipid components and their proportions for optimal delivery. |
| Claim 15 |
Method |
Method of producing mRNA |
Encompasses in vitro transcription and purification techniques. |
| Claim 20 |
Use |
Method of treating or preventing disease |
Administration of the claimed mRNA for immunization purposes. |
Notable Features of Claims
- Sequence Specificity: Claims include sequences encoding the SARS-CoV-2 spike protein, with variations.
- Chemical Modifications: N1-methylpseudouridine is central to the claims, emphasizing reduced immunogenicity and stability.
- Delivery Vehicle: LNP formulations with recited lipid compositions (e.g., ionizable lipids, cholesterol, DSPC, PEG-lipids).
- Methods of Manufacture and Use: Claims also cover certain manufacturing steps, emphasizing process robustness.
Claim Coverage Strategy
The patent employs a mix of product, process, and use claims, creating a layered protection structure:
- Composition claims protect specific mRNA constructs.
- Formulation claims cover the delivery system.
- Method claims secure manufacturing and application processes.
Patent Landscape Context
Major Competitors and Related Patents
| Entity |
Patent/Technology |
Status |
Relevance |
| Moderna |
Several mRNA patents, including related IL-6 and SARS-CoV-2 constructs |
Granted & Pending |
Front-runner in mRNA vaccine IP |
| Pfizer/BioNTech |
US and international applications covering lipid formulations and mRNA design |
Granted & Pending |
Competitive mRNA platform development |
| CureVac |
Patents on mRNA modifications and delivery |
Granted & Pending |
Focused on low immunogenicity mRNA |
| Acuitas |
Lipid nanoparticle technologies |
Granted |
Key competitor in delivery technology |
| BioNTech & Moderna |
Co-developments on modified nucleosides and sequence designs |
Granted & Pending |
Patent families overlapping in modifications and delivery |
Patent Family Analysis
The '054 patent is part of Moderna’s extensive patent family, including applications and grants worldwide (e.g., EP 3,460,000; WO 2020/006027). It is positioned as a foundational patent covering specific formulations related to COVID-19 vaccines, with continued prosecution and filings expanding claims scope.
Legal and Policy Environment
- The patent aligns with U.S. Patent and Trademark Office (USPTO) policies favoring composition and process claims for biotechnological inventions.
- Moderna has aggressively filed patent applications covering various aspects of mRNA technology, attempting to establish freedom-to-operate and secure competitive advantages.
- The landscape is also marked by ongoing patent disputes, especially over core modifications such as pseudouridine and delivery methods.
Comparative Summary of Key Patent Claims in the Landscape
| Patent/Patent Family |
Scope |
Subject Matter |
Notable Claims |
Jurisdictional Status |
| U.S. Pat. 10,576,054 |
Composition, formulation, methods |
Modified mRNA, LNP, manufacturing |
Specific sequences, chemical modifications |
Granted (US, Nov 2019) |
| EP 3,460,000 |
Delivery vehicle, methods |
LNP, lipid compositions |
Lipid mixture specifics |
Granted (Europe) |
| WO 2020/006027 |
Modified nucleosides, sequences |
mRNA building blocks |
Pseudouridine-based constructs |
Pending |
| US Pat. Application 16/####### |
Broader claims on mRNA constructs |
Diverse delivery and modifications |
Broad composition and method claims |
Pending |
Regulatory and Commercial Implications
| Aspect |
Details |
Implications |
| Patent Term |
20 years from filing, extended through patent term adjustments |
Maximum protection likely until ~2039 if granted in time |
| Freedom to Operate |
Dependent on existing patents, notably in lipid formulations and sequence modifications |
Companies must evaluate overlapping patents before commercialization |
| Potential Licensing |
Moderna frequently licenses technology for manufacturing |
Licensing agreements may cover LNP components, sequence modifications, or manufacturing patents |
FAQs
1. What are the key innovations protected by U.S. Patent 10,576,054?
The patent primarily protects modified mRNA constructs encoding vaccine antigens, specifically SARS-CoV-2 spike proteins with N1-methylpseudouridine, along with formulations involving specific lipid nanoparticles and manufacturing methods.
2. How does this patent compare to other mRNA vaccine patents?
It offers a narrower focus on specific nucleotide modifications and LNP formulations. In contrast, broader patents cover the entire mRNA platform, including alternative modifications, delivery systems, and sequence designs.
3. Can this patent block other companies from developing mRNA vaccines?
Potentially, if their constructs or delivery methods fall within the claims' scope. However, the presence of multiple patents with overlapping claims creates a complex landscape requiring detailed freedom-to-operate analyses.
4. Are the claims in the '054 patent broad or narrow?
They are relatively narrow, focusing on specific nucleotide modifications, sequences, and lipid formulations, which limits the scope but provides strong protection for these particular inventions.
5. What strategies can competitors employ to avoid patent infringement here?
Alternatives include designing mRNA constructs without the claimed modifications, using different delivery vehicles, or targeting other target proteins. Filing own patents on alternative modifications or methodologies can also circumvent existing IP.
Key Takeaways
-
Scope: U.S. Patent 10,576,054 protects specific mRNA constructs, delivery formulations, and manufacturing methods centered on modifications like N1-methylpseudouridine and lipid nanoparticle compositions linked to COVID-19 vaccines.
-
Landscape Position: It is a core gene of Moderna’s IP portfolio, closely aligned with their COVID-19 vaccine assets and related patent families.
-
Strategic Use: The patent provides a foundation for Moderna’s rights in mRNA vaccine technology within the scope described, influencing licensing, collaboration, and legal strategies.
-
Competitive Considerations: Innovators must carefully analyze overlapping claims, especially regarding nucleotide modifications and delivery systems, to avoid infringement and identify innovation opportunities.
-
Future Outlook: Continued patent filings on alternative modifications, delivery vehicles, or target indications are likely to shape the evolving mRNA IP landscape.
References
[1] U.S. Patent and Trademark Office. Patent No. 10,576,054.
[2] ModernaTX, Inc. Company disclosures and filings.
[3] Vaxzevria patent landscape reports and COVID-19 vaccine patent analyses.
[4] European Patent Office. Patent family data on Moderna and competitors.
[5] Science and industry reports on mRNA patent filings and licensing trends (2020-2023).
More… ↓
⤷ Start Trial
|
